July 19 - 22, 2019
Hyatt Regency San Francisco
San Francisco, California
Abstract submission deadline: Wednesday, May 1
Advance registration deadline: Friday, June 7
Friday, July 19, 2019
Saturday, July 20, 2019
Sunday, July 21, 2019
Monday, July 22, 2019
Next generation CAR T cellsCrystal L. Mackall, Stanford University, Stanford, California
A path towards successful T cell therapy for solid cancers Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas
Opening Reception7-9 p.m.
Top of page
Saturday, July 20Continental Breakfast7-8 a.m.
1: Cellular Therapy Clinical Updates ISession Chair: Christine E. Brown, City of Hope National Medical Center, Duarte, California8-10 a.m.
Chimeric antigen receptor T cell therapy for chronic lymphocytic leukemiaSaar I. Gill, University of Pennsylvania, Philadelphia, Pennsylvania
CAR-T antigen evasion: The emerging role for multi-targeted CAR therapyDavid B. Miklos, Stanford University, Stanford, California
Advancing CAR T cell therapy for treatment of brain tumorsChristine E. Brown
Targeting pancreatic cancer using nonengineered, multiantigen-specific T cells (TACTOPS)*Brandon G. Smaglo, Baylor College of Medicine, Houston, Texas
Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)*Anna Nowak, Immatics Biotechnologies GmbH, Tübingen, Germany
2: CAR T Cell Engineering – Barriers for Targeting Solid TumorsSession Chair: Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, Washington10:30 a.m.-12:30 p.m.
Engineering lymphocytes for the adoptive immunotherapy of solid tumorsStephen Gottschalk, St. Jude Children’s Research Hospital, Memphis, Tennessee
Molecular and epigenetic programs defining tumor-specific T cell dysfunction and therapeutic reprogrammabilityAndrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York
Engineering T cells to eradicate tumors: It starts with the TCR but doesn't stop therePhilip D. Greenberg
HER2-specific chimeric antigen receptor T cells with NKILA knockout improves therapeutic effects towards HER2+ breast cancer*Erwei Song, Sun Yat-sen University, Guangzhou, China
Regulation of CD40L on chimeric antigen receptor T cells enhances immune function translating to antitumor effects* Michelle Fleury, Obsidian Therapeutics, Cambridge, Massachusetts
Poster Session A / Lunch12:30-2:30 p.m.
Plenary Session 3: Scalability of T Cell Therapy – Driving Down CostsSession Chair: Barbra J. Sasu, Allogene Therapeutics, San Francisco, California2:30-4 p.m.
Allogene: Leading the next revolution in cell therapyBarbra J. Sasu
Scalability of T cell therapyGwendolyn Binder-Scholl, Cabaletta Bio, Philadelphia, Pennsylvania
Innovating and planning our way to improve affordability and accessibility for chimeric antigen receptor (CAR) T cell therapiesHeidi Zhang, Celgene Corporation, Seattle, Washington
4: NK and Other Immune Cell TherapiesSession Chair: Catherine M. Bollard, Children’s National Health System, Washington, D.C.4:30-6:30 p.m.
Off-the-shelf CAR-engineered cord blood-derived NK cells for the treatment of cancerKaty Rezvani, The University of Texas MD Anderson Cancer Center, Houston, Texas
TGFβ-resistant T and NK cells for cancerCatherine M. Bollard
Selective expansion of adaptive natural killer cells for cancer immunotherapy
Karl Johan Malmberg, The University of Oslo, Oslo, Norway
ACTR and BOXR T-cell therapies: Addressing the challenges of solid tumors*Heather Huet, Unum Therapeutics, Cambridge, Massachusetts
Targeting the chemokine receptor CCR4 using chimeric antigen receptor T cells for the treatment of CCR4+ T-cell malignancies*Marissa Del Real, City of Hope, Duarte, California
Top of pageSunday, July 21Continental Breakfast7-8 a.m.
Plenary Session 5: Cellular Therapy Clinical Updates IISession Chair: Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas8-10 a.m.
CAR T-cell therapy for lymphomas: Current and future strategiesSattva S. Neelapu
Expanding CAR T cell therapy to a wide spectrum of pediatric malignanciesJulie R. Park, Seattle Children's Hospital, Seattle, Washington
Addressing relapse associated with leukemic resistance to CAR T cellsTerry J. Fry, University of Colorado Denver and Children's Hospital Colorado, Aurora, Colorado
Predicting CD19Neg relapse following CAR T-cell therapy in B-cell precursor acute lymphoblastic leukemia*Pablo Domizi, Stanford University School of Medicine, Stanford, California
Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers*Harpreet Singh (presenting on behalf of Apostolia Tsimberidou), Immatics US, Inc., Houston, Texas
Plenary Session 6: Optimization of Target Antigens for TCR and TILSession Chair: Alex Franzusoff, PACT Pharma, Inc., South San Francisco, California10:30 a.m.-12:15 p.m.
Novel naturally presented targets for personalized T-cell therapiesHarpreet Singh, Immatics US, Inc., Houston, Texas
Personalized neoantigen-targeting adoptive TCR-T cell therapies for solid tumorsAlex Franzusoff
Personalized gene editing of T cells to express neoantigen-specific TCRs isolated from peripheral blood of patients on PD-1 blockade therapy*Cristina Puig-Saus, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
Finding CAR-T drivers for GBM: Building a translational discovery pipeline*Sheila Kumari Singh, McMaster University Medical Center, Hamilton, Ontario, Canada
Immunopeptidomics and peptide expression profiles to develop T-cell receptors against glioma-associated antigens*Diego A. Carrera, University of California San Francisco School of Medicine, San Francisco, California
Lunch on Own12:15-2:30 p.m.
7: Combination Therapy with Adoptive Cell TherapySession Chair: Ivan M. Borrello, Johns Hopkins University, Baltimore, Maryland2:30-4:30 p.m.
Unveiling mechanisms of response and resistance to instruct next generation cancer immunotherapyAude G. Chapuis, Fred Hutchinson Cancer Research Center, Seattle, Washington
Marrow-infiltrating lymphocytes: Biology and practiceIvan M. Borrello
Combining checkpoint blockade with CAR T cell therapy to augment responseShannon L. Maude, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditioning treatment with a CD27 antibody enhances in vivo expansion and antitumor activity of adoptively transferred T cells*Li-Zhen He, Celldex Therapeutics, Inc., Hampton, New Jersey
IL-2 limits CAR T-cell efficacy through selective expansion of a differentiated and less functional subset marked by the loss of CD27 expression*Dongrui Wang, City of Hope, Duarte, California
Poster Session B / Reception4:30-6:30 p.m.Top of page
Monday, July 22
Continental Breakfast7-8 a.m.
Plenary Session 8: Enhancing Immune Cell Function through Genetic EngineeringSession Chair: Rodabe N. Amaria, The University of Texas MD Anderson Cancer Center, Houston, Texas8-10 a.m.
Tumor infiltrating lymphocyte therapy for metastatic melanomaRodabe N. Amaria
Enhancing CAR T cell therapy by enabling CAR T cell interaction with antigen-presenting cellsClare Y. Slaney, Peter MacCallum Cancer Center, Melbourne, Australia
Strategies to improve CAR T persistence and solid tumor targetingAvery D. Posey, Jr., University of Pennsylvania, Philadelphia, Pennsylvania
Convertible CAR-T cells provide a highly modular universal system for dose control of activity, targeting flexibility, and in vivo CAR maintenance*Kaman Kim, Xyphos Biosciences, San Francisco, California
Adapter CAR T cells (AdCAR-T) allow precise control on effector function, prevent antigen evasion, and enable differential target cell lysis, based on complex antigen expression profiles*Christian M. Seitz, University Children's Hospital Tübingen, Tübingen, Germany
Plenary Session 9: Novel Approaches for Gene Delivery (Engineered Vectors and Viral Delivery Systems)Session Chair: Laurence J.N. Cooper, Ziopharm Oncology, Boston, Massachusetts10:30 a.m.-12 p.m.
T cells genetically modified using non-viral gene transfer to target cancerLaurence J.N. Cooper
Reprogramming human immune cell circuitryAlexander Marson, University of California San Francisco, San Francisco, California
Engineering smarter and stronger T cells for cancer immunotherapyYvonne Y. Chen, University of California Los Angeles, Los Angeles, California
Closing Remarks12 p.m.
*Short talk from proffered abstractTop of page